Value Drug Company files US antitrust claims against Bausch, Teva over Xifaxan
MLex Summary: Value Drug Company filed US antitrust claims accusing Bausch Health and Teva Pharmaceuticals of entering into an illegal pay-for-delay agreement to keep a generic competitor to Bausch’s irritable-bowel-syndrome treatment Xifaxan...To view the full article, register now.
Already a subscriber? Click here to view full article